Contribution to sustainable development
- BioGaia’s business mission is based on making a successful contribution for improved health and well-being for people with digestive or oral health problems. Probiotics can also be used as preventive measures, to strengthen the immune system, which can help reduce the use of antibiotics and thus lessen the risk of antibiotic resistance.
- BioGaia has an active sustainability commitment in the fight against antibiotic resistance.
- Expectations on companies to accept responsibility and contribute to the sustainable development of society are increasing. There are also demands for clear communication with structured and visible sustainability initiatives.
- The UN’s 2030 Agenda, with 17 Sustainable Development Goals (SDGs) was adopted on 1 January 2016. The SDGs where BioGaia contributes and has the best possibility to influence are “Good health and well-being” and “Responsible consumption and production”.
BioGaia contributes to improved well-being with probiotic bacteria that make a difference to digestive and oral health. The products are safe and clinically tested, of high quality and sold in smart packages.
BioGaia builds long-term and close partner relationships with distributors who are in place where the products are sold. BioGaia supports distributors within sales and marketing.
BioGaia collaborates with researchers at more than 50 universities and clinics in a unique, global network. All studies must have ethical approval and BioGaia encourages researchers to publish their results but otherwise has no influence on the studies.
A high and consistent product quality is ensured through long-term and close relationships with a small number of suppliers. In addition, development and improvement work is carried out in close collaboration with suppliers.
BioGaia offers its employees a stimulating workplace with a culture in which each individual has an opportunity to develop and influence his or her work situation. A good balance between work and leisure lays the foundation for the long-term health of employees.
Through good risk management, controlled costs, and integrated sustainability initiatives, BioGaia will increase shareholder value and continue its profitable growth
through its strong business model.
To date, 202 clinical studies using BioGaia’s human strains of Lactobacillus reuteri have been performed on 17,200 individuals of all ages.
BioGaia’s products are sold in around 100 countries. The largest segment is paediatrics, accounting for over 80 per cent of total sales.